Published studies have investigated Semaglutide across a broad range of metabolic research areas, including obesity, body-weight regulation, appetite signalling, glucose metabolism, type 2 diabetes, cardiovascular outcomes, fatty liver disease and long-term incretin biology
A recent study compared semaglutide and tirzepatide for weight loss and found that tirzepatide resulted in 2.4% more weight loss at 3 months, 4.3% more at 6 months, and 6.9% more at 12 months
The endothelial adhesion molecules ICAM-1 and VCAM-1 play a central role in allowing white blood cells to stick to and move through the endothelium
Start simple by prepping components (proteins, grains, and chopped vegetables) that you can mix and match throughout the week rather than full meals
Retatrutide is still investigational
Clinical trials have documented substantial weight loss with these medicationstypically 15% of body weight with semaglutide 2.4 mg (STEP 1 trial) and approximately 21% with tirzepatide 15 mg (SURMOUNT-1 trial) at 72 weeks
